As of 2018, the best chance PDAC patients have at long-term survival is radical resection followed by adjuvant chemotherapy, lead author Lois A. Daamen, MD, and colleagues wrote in the journal. But even after resection, only 12 to 27 percent of patients manage to achieve five-year survival, and 80 percent see local or distant disease recurrence—stats the authors call “dismal.” Read more . . .
In a medical landscape where the prognosis of pancreatic ductal adenocarcinoma (PDAC) remains poor, postoperative CT and FDG PET-CT imaging could help detect disease recurrence, researchers reported in the European Journal of Radiology this summer.